Tekmira Merges With OnCore In Hopes Of Building Hepatitis B Powerhouse
This article was originally published in The Pink Sheet Daily
Executive Summary
The two small biotechs are coming together to create a hepatitis B-focused company that management hopes will mirror the success seen with hepatitis C companies.